Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15469 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Richard J Drew und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Innovation Unit, Rotunda Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections, Anti-Bacterial Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Mycoplasma genitalium is an emerging pathogen, which has been linked to cervicitis, urethritis and pelvic inflammatory disease (PID). With the advent of multiplex polymerase chain reaction (PCR) panels for sexually transmitted infections, it is increasingly being identified in pregnant women.
Objectives
The aim was to review international guidelines, which had explicit recommendations for treatment of M. genitalium infection in pregnancy and breastfeeding. Search Strategy PubMed, EMBASE and Cochrane databases were reviewed with no age, species, language or date restrictions. Selection Criteria Studies were included if they had an explicit recommendation for treatment of M. genitalium in pregnancy. Studies were excluded if there was no recommendation in pregnancy, if they referred to other international guideline recommendations or were historical versions of guidelines. Data Collection and Analysis References were manually reviewed and 50 papers were selected for review. Only four guidelines were included in the final analysis and they were from Europe, UK , Australia and Aotearoa New Zealand. Main Results All studies recommended azithromycin as first‐line treatment, and advised against moxifloxacin use. The dosing schedule of azithromycin, varied between guidelines, as did the utility/safety of pristinamycin for macrolide resistant infections. Safety data was generally reassuring for azithromycin but inconsistent for pristinamycin.
Conclusions
Azithromycin is the first‐line treatment for macrolide susceptible or unknown resistance infections, but there is a lack of consistency regarding dosing of azithromycin or the utility/safety of pristinamycin for macrolide resistant infections in pregnancy/lactation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Innovation Unit, Rotunda Hospital, Dublin, Ireland.
- Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Dublin, Ireland.
- Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Obstetrics and Gynecology, Rotunda Hospital, Dublin, Ireland.
ORCID-Profile: Richard J Drew
Zitieren
APA
Drew, R. J., & Eogan, M. (2024). Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15469
Vancouver
Drew RJ, Eogan M. Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15469
BibTeX
@article{Drew2024,
author = {Drew, Richard J and Eogan, Maeve},
title = {Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15469}
}
EUVIMED